Search

This book covers all diagnostic and therapeutic aspects of neuro-oncological diseases. In the last decade, the management of brain tumors has been revolutionized following the new WHO classification and thanks to the introduction of molecular markers into the clinical routine. From an imaging point of view, the continuous technological developments and the implementation of various radiopharmaceuticals have paved the way to new clinical indications and has helped optimize patient management. In this context, a major breakthrough could derive from the introduction of radiomics and artificial intelligence in the diagnostic and therapeutic pathway. Not forgetting the emerging role of heavy-ion therapy as a complement to the innovative drugs and treatments adopted in medical oncology and radiation therapy. In the present book, all above-mentioned aspects are covered, starting with the novel standards for the WHO classification of brain tumors, to the up-to-date surgical techniques and advanced therapeutic approaches, passing through the currently available imaging modalities and ongoing developments embracing both radiology and nuclear medicine discipline. Imaging represents indeed the “trait d'union” for all the arguments described in the book; therefore, in most chapters there are dedicated sessions focused on the role of imaging in each specific context. The publication aims to fill the gap between the clinicians and all professionals directly involved in the management of patients with brain tumors and the newest scientific outreach. Moreover, thanks to the comprehensive insight into the latest technological developments, scientists and researchers interested in the topic will find the book a useful tool for future studies and perspective discoveries.

This new atlas, the fourth of a successful series, is a completely revised and updated edition of a previously published FDG PET-CT atlas. In the past few years, considerable progress has been made in the field of PET-CT imaging, and this new edition takes full account of these recent developments. Furthermore, its educational mission has been broadened: beyond serving as a straightforward guide to FDG PET-CT imaging it now encompasses the integrative use of contrast-enhanced CT and MRI. The new edition also includes non-oncological indications for FDG PET-CT.The atlas aims to help imaging practitioners to recognize physiological and benign pathological FDG uptake and illustrates in a case-based, practical manner the PET-CT appearances of all the major tumors and infectious, inflammatory, and neurodegenerative disorders. The main clinical applications are covered, and learning points and pitfalls are clearly articulated. The consistent, user-friendly format facilitates imageinterpretation and allows rapid review of key information needed for FDG PET-CT imaging.

Using SWOT analysis, this book examines in detail the strengths and weaknesses of the hybrid modalities PET-CT and PET-MRI for imaging of the central nervous system, comparing their merits and evaluating their advantages over the stand-alone modalities. The aim is to employ a truly systematic approach in order to define the potential clinical benefit of these modalities and to identify shortcomings, opportunities, and threats. Clinical application of the modalities is explored in a range of conditions, including dementia and related disorders, movement disorders, psychiatric disorders, cerebrovascular disease, infection/inflammation, brain tumors, and pediatric neurologic disorders. In addition, the basics of hybrid imaging are addressed, covering physics, instrumentation, data analysis and quantitation, radiopharmaceuticals, and contrast media. PET-CT and PET-MRI in Neurology, written by experts from Europe and the United States, will be essential reading for imaging specialists and of value for neurologists, psychiatrists, neurosurgeons, and pediatricians.

This book provides a comprehensive state-of-the-art review of pediatric nuclear medicine, encompassing both diagnostic and therapeutic applications. Detailed attention is paid to the role of FDG PET-CT within oncology, but a variety of other long-established or less frequently used diagnostic procedures are also covered. Each indication is critically discussed from a clinical perspective, with analysis of benefits and limitations and comparison against the information yield of alternative techniques. The coverage of therapy based on radiopharmaceuticals includes the most relevant current strategies, including those utilizing radioiodine, MIBG, or radiolabelled peptides. In addition, issues concerning the radiation risk of nuclear medicine procedures in children are addressed. All chapters have been written by international experts and include the most up-to-date scientific and clinical information.

The field of nuclear medicine has evolved rapidly in recent years, and one very important aspect of this progress has been the introduction of hybrid imaging systems. PET-CT has already gained widespread acceptance in many clinical settings, especially within oncology, and now SPECT-CT promises to emulate its success. Useful applications of this new approach have been identified not only in oncology but also in endocrinology, cardiology, internal medicine, and other specialties. This atlas, which includes hundreds of high-quality images, is a user-friendly guide to the optimal use and interpretation of SPECT-CT. The full range of potential SPECT-CT applications in clinical routine is considered and assessed by acknowledged experts. The book is designed to serve as a reference text for both nuclear physicians and radiologists; it will also provide fundamental support for radiographers, technologists, and nuclear medicine and radiology residents.

Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clinical practice. This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG. A wide range of tracers is covered, such as 18F- and 11C-choline, 11C-methionine, 18F-ethyl-L-tyrosine, 68Ga-DOTA-NOC, 11C-acetate, 11C-thymidine, and 18F-DOPA. Throughout, the emphasis is on image interpretation, with guidance on the recognition of normal, benign, and malignant uptake and clear instruction on learning points and pitfalls. This atlas is designed to serve as a reference text for both nuclear physicians and radiologists, and will also be of great benefit to radiographers, technologists, and nuclear medicine and radiology residents.

This user-friendly atlas, featuring about 500 images, should be a quick guide to interpreting PET/CT images with FDG in oncology. It also illustrates how to recognize normal, para-physiological, and benign pathological uptakes in a case-based practical manner. The text, which includes most relevant technical and pathophysiological premises, covers the main clinical applications and clearly articulates learning points and pitfalls. This atlas aims to become a standard text for nuclear medicine physicians and radiologists, residents and technicians whose work involves PET/CT imaging. This book is also suitable for both undergraduate and postgraduate courses.